Extract Interstitial lung diseases (ILDs) encompass a heterogeneous group of inflammatory and fibrotic conditions. The ILD diagnostic ontology based on morphological features of radiology and histopathology with identification of secondary aetiologies has evolved over the past decades, forming the basis of patient care [1 - 3].
Besides the diagnostic label, importance of disease behaviour in ILD care is well-established, with the introduction of its classification in 2013 [2] and guidelines for progressive pulmonary fibrosis (PPF) more recently [4]. In addition, sporadic events, such as acute exacerbation of ILD [5], can accelerate the disease process.
Thus, serial monitoring is a core component in ILD care, with a multifaceted approach of symptom, physiological and radiological assessments. Existing monitoring strategies centre on scheduled periodic in-person evaluations.
This poses risks of delayed recognition of disease progression and subsequent treatment initiation, which may adversely impact patient outcomes. In addition, the growing prevalence of ILD globally raises concerns of difficulty accessing specialist care [6 - 9].
More flexible and patient-centred monitoring strategies are therefore needed.
European Respiratory Journal published a clinical update in Critical Care on 02 Apr 2026. The item focuses on ERJ advances: home monitoring in interstitial lung disease. Open the detail page to review the full original feed content.